Abnormal activation of fibroblasts in mature scars after myocardial infarction is a key etiological factor in tissue repair disorders. Here, the authors developed a BBIR-T cell therapy that precisely targets pathogenic fibroblast subpopulations, thereby delaying ventricular remodeling and deterioration of cardiac function.
